Prostate Cancer and Tumors

At the CyberKnife Institute at Mercy Hospital we make it possible to treat patients and tumors inappropriate for invasive surgery, or more effectively treated with the advanced technology of the Cyberknife. The capabilities of the CyberKnife to track the tumor’s true location during treatment and continually adjusts for movements of the body, is a unique technology that permits Radiosurgery on tumors anywhere in the body. The CyberKnife’s Synchrony System provides unprecedented accuracy that also extends to the treatment of tumors which move with the body as an individual breathes in respiration, due to the Cyberknife’s technology that “learns” and matches patients’ respiratory patterns, and accounts for them, allowing the precise dose to always be targeted at the tumor, making Cyberknife highly effective for prostate cancer and tumors.

CyberKnife differs from radiation therapy, which irradiates both normal and cancerous tissues. CyberKnife delivers an ablative dose to the tumor with submillimeter accuracy and minimal exposure of normal tissue. As a result, we can treat inoperable patients, shrink tumors for less radical resections, destroy radioresistant tumors and treat patients previously treated with radiation. In addition, patients experience short, painless treatments with far fewer side effects, limited (if any) downtime and an immediate return to activities.

If you are interested in a second opinion on your medical condition, click here to Ask Dr. Berti.

CyberKnife prostate radiosurgery effectively addresses shortcomings of other treatments for early stage prostate cancer. It is less invasive, with faster recovery than radical prostatectomy, vastly shorter in duration and with sharper treatment margins compared with external beam radiotherapy, potentially less urologically traumatic and obstructive than permanent source brachytherapy, and less invasive than HDR brachytherapy.

With CyberKnife, the range of tumors treatable with stereotactic Radiosurgical ablation is unprecedented.